Aclaris Therapeutics
ACRS
149 hedge funds and large institutions have $630M invested in Aclaris Therapeutics in 2026 Q2 according to their latest regulatory filings, with 28 funds opening new positions, 65 increasing their positions, 32 reducing their positions, and 14 closing their positions.
186% more call options, than puts
Call options by funds: $3.38M | Put options by funds: $1.18M
103% more repeat investments, than reductions
Existing positions increased: 65 | Existing positions reduced: 32
100% more first-time investments, than exits
New positions opened: 28 | Existing positions closed: 14
67% more funds holding in top 10
Funds holding in top 10: 3 → 5 (+2)
54% more capital invested
Capital invested by funds: $409M → $630M (+$221M)
10% more funds holding
Funds holding: 136 → 149 (+13)
5.25% less ownership
Funds ownership: 90.56% → 85.31% (-5.3%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$26.4M |
| 2 |
BlackRock
New York
|
+$11.7M |
| 3 |
SCM
Silverarc Capital Management
Boston,
Massachusetts
|
+$8.68M |
| 4 |
JHC
Jones Hill Capital
New York
|
+$7.85M |
| 5 |
State Street
Boston,
Massachusetts
|
+$5.56M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$11.6M |
| 2 |
BCM
BML Capital Management
Zionsville,
Indiana
|
-$10.1M |
| 3 |
Balyasny Asset Management
Chicago,
Illinois
|
-$5.97M |
| 4 |
Marshall Wace
London,
United Kingdom
|
-$2.67M |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$2.17M |
ACRS Hedge Fund Activity: Q2 2026 in Review
149 of the 8,286 institutional investors tracked by Wall St. Rank reported a position in Aclaris Therapeutics (ACRS) for Q2 2026, worth a combined $630M — up 54% from $409M a quarter earlier.
Buyers outnumbered sellers: 28 funds opened new ACRS positions and 14 closed out — a net gain of 14 holders — while 65 added to existing stakes and 32 trimmed.
The largest buyer was RA Capital Management, adding an estimated $26.4M. The largest seller was Morgan Stanley, cutting an estimated $11.6M.
- 149 institutional investors held Aclaris Therapeutics (ACRS) as of Q2 2026, up from 136 in Q1 2026.
- Funds reported $630M of Aclaris Therapeutics stock for Q2 2026, up 54% quarter-over-quarter.
- 28 funds opened new Aclaris Therapeutics positions in Q2 2026 and 14 closed out, a net change of +14 holders.
- The largest Aclaris Therapeutics buyer in Q2 2026 was RA Capital Management, an estimated $26.4M added.
- The largest Aclaris Therapeutics seller in Q2 2026 was Morgan Stanley, an estimated $11.6M sold.
Based on aggregated 13F filings for Q2 2026.